94 completed, 8 recruiting, 8 unknown, 3 active not recruiting. 36 Phase 3, 27 Phase 2, 24 Phase 1, 21 Phase 4, 6 Not applicable.
Follow dulaglutide: new trials by email Literature Review of dulaglutide trials Research Report on dulaglutide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus PG-102(MG12), Dulaglutide - Type 2 Diabetes | Phase 2 | Not yet recruiting | ProGen. Co., Ltd. | 60 | 2026-10-01 | 2026-07-01 |
| A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes Orforglipron, Dulaglutide - Diabetes Mellitus, Type 2 | Phase 3 | Recruiting | Eli Lilly and Company | 170 | 2026-07-08 | 2026-10-19 |
| Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease Dulaglutide, SGLT2i, Finerenone - T2DM (Type 2 Diabetes Mellitus), CKD - Chronic Kidney Disease | Phase 4 | Not yet recruiting | First Affiliated Hospital of Wannan Medical College | 468 | 2026-05-01 | 2026-04-22 |
| Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data. Dulaglutide, Sitagliptin - Type 2 Diabetes | Completed | Brigham and Women's Hospital | 300000 | 2026-02-03 | 2026-07-10 | |
| INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD) Dulaglutide, Semaglutide, Tirzepatide - Type 2 Diabetes, Overweight | Completed | Brigham and Women's Hospital | 60000 | 2026-01-27 | 2026-07-09 | |
| Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk Semaglutide, Dulaglutide - Type 2 Diabetes Mellitus, Obesity | Completed | Brigham and Women's Hospital | 120000 | 2026-01-20 | 2026-07-09 | |
| A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus Dulaglutide - Type 2 Diabetes Mellitus (T2DM) | Phase 1 | Completed | Eli Lilly and Company | 20 | 2025-12-29 | 2026-08-21 |
| Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis Dulaglutide - Intracranial Atherosclerosis, Stroke, Ischemic | Phase 2 / Phase 3 | Recruiting | National University of Singapore | 130 | 2025-12-17 | 2025-12-23 |
| Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes Dulaglutide, Semagludtide, Tirzepatide - Non-diabetec Obesity, Obesity (Disorder) | Phase 3 | Completed | Zagazig University | 150 | 2025-11-14 | 2026-09-22 |
| Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial Dulaglutide 1.5 MG/ML, Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution, Tirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physician - Obese Diabetics, Obese Non Diabetic | Phase 3 | Completed | Zagazig University | 159 | 2025-10-18 | 2026-09-15 |
| A Phase 3 Study of HS-20094 in Patients With T2DM HS-20094 Injection, Dulaglutide Injection - Type 2 Diabetes | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 546 | 2025-09-30 | 2025-09-05 |
| Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes Mellitus Dulaglutide - Menstrual Irregularities, Type1 Diabetes Mellitus | Phase 1 / Phase 2 | Enrolling by invitation | Ain Shams University | 50 | 2025-08-04 | 2026-06-05 |
| Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. Metformin, Dulaglutide, Semaglutide 1.0 mg - Diabetes Mellitus Type 2 | Phase 4 | Completed | Fundación para la Investigación del Hospital Clínico de Valencia | 92 | 2025-05-26 | 2026-09-04 |
| A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin HDM1005 1, HDM1005 2, HDM1005 3 - Type 2 Diabetes | Phase 2 | Recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 216 | 2025-04-30 | 2025-08-17 |
| A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) Dulaglutide - Type 2 Diabetes | Phase 3 | Recruiting | Eli Lilly and Company | 55 | 2025-01-10 | 2026-08-07 |
| Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists SGLT-2 inhibitor, GLP1-RA - Type 2 Diabetes (T2DM) | Phase 4 | Active not recruiting | MaryAnn Banerji | 60 | 2024-12-21 | 2026-01-08 |
| Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia Dulaglutide 0.75Mg/0.5Ml Inj Pen, control group (insulin) - Transfusion Dependent Beta Thalassemia | Phase 2 | Completed | Ain Shams University | 80 | 2024-11-22 | 2026-01-27 |
| Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes Tirzepatide, Dulaglutide, Semaglutide - Type 2 Diabetes | Completed | Brigham and Women's Hospital | 70000 | 2024-11-01 | 2026-09-18 | |
| Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk Tirzepatide, Dulaglutide, Semaglutide - Type 2 Diabetes, Overweight | Completed | Brigham and Women's Hospital | 887132 | 2024-10-01 | 2025-10-15 | |
| Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data Tirzepatide, Dulaglutide - Type 2 Diabetes, Major Adverse Cardiac Events | Completed | Brigham and Women's Hospital | 44671 | 2024-10-01 | 2025-10-15 |
Showing 20 of 120. Sign in to see all of them.
Diabetes Mellitus, Type 2 (93) · Diabetes Mellitus (12) · Obesity (11) · Overweight (6) · Renal Insufficiency, Chronic (4) · Cardiovascular Diseases (3) · Glucose Metabolism Disorders (3) · Metabolic Diseases (3) · Non-alcoholic Fatty Liver Disease (3) · Diabetes Mellitus, Type 1 (2) · Diabetic Nephropathies (2) · Endocrine System Diseases (2) · Glucose Intolerance (2) · Hyperglycemia (2) · Albuminuria (1)
Eli Lilly and Company (56) · Brigham and Women's Hospital (7) · University Hospital, Basel, Switzerland (4) · Innovent Biologics (Suzhou) Co. Ltd. (3) · Novo Nordisk A/S (3) · Ain Shams University (2) · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (2) · Emory University (2) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (2) · Sanofi (2) · Zagazig University (2) · AdventHealth Translational Research Institute (1) · Attikon Hospital (1) · Beijing Dongfang Biotech Co., Ltd. (1) · Cardenal Herrera University (1)
United States (54) · China (24) · Mexico (20) · Puerto Rico (19) · Spain (17) · Germany (14) · Poland (14) · Hungary (13) · Romania (13) · India (11) · Japan (11) · Argentina (10) · Brazil (9) · Canada (9) · Czechia (9)
Shirley Wang, PhD, ScM (5) · Mirjam Christ-Crain, Prof (2) · Absalon D Gutierrez, MD (1) · Alp Ikizler, MD (1) · Ana Checa-Ros, MD, PhD (1) · Andrea Kelly, MD, MSCE (1) · Bettina Winzeler, Dr. (1) · Bettina Winzeler, Dr. med. (1)
PMID 26691396, PMID 27161178, PMID 36894938, PMID 39963952, PMID 28357715, PMID 25018121, PMID 26089386, PMID 28606095, PMID 29430801, PMID 32277401, PMID 32621083, PMID 32857293, PMID 35134170, PMID 35210595, PMID 41207920, PMID 22025886, PMID 22431131, PMID 22554256, PMID 23294774, PMID 23383649, PMID 24742660, PMID 24762094, PMID 24842985, PMID 25482832, PMID 25912221, PMID 26009229, PMID 27732328, PMID 27916783, PMID 28573765, PMID 28755389, PMID 29110972, PMID 29246950, PMID 29264713, PMID 29310645, PMID 29397376, PMID 29483060, PMID 29557057, PMID 29693361, PMID 29764222, PMID 29910024, PMID 30293770, PMID 30362224, PMID 30473097, PMID 30615985, PMID 30949907, PMID 31183384, PMID 31189509, PMID 31189511, PMID 31215727, PMID 31228090
2016 (3), 2017 (3), 2014 (2), 2019 (2), 2025 (2), 2009 (1), 2015 (1), 2018 (1), 2023 (1), K23DK122199 (1), K23DK131327 (1), K23GM128221 (1), R21DK122234 (1)